MALIGNANT MESOTHELIOMA MARKET ANALYSIS BY TYPE, APPLICATION, REGIONS AND COMPANIES FORECAST
2024-09-13 | Pages: 200+ | Report ID: WR-2024-09-13-34460 | Healthcare
Historical data: 2018 - 2023
Forecast period: 2024 - 2031
Quantitative units: Revenue in USD million and CAGR from 2024 to 2031
Report coverage: Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Malignant Mesothelioma Market
1.1 SCOPE OF THE REPORT
1.2 MARKET SEGMENT ANALYSIS
1.3 REGULATORY SCENARIO BY REGION/COUNTRY
1.4 MARKET INVESTMENT SCENARIO STRATEGIC
1.5 MARKET ANALYSIS BY TYPE (USD MILLION)
1.6 MARKET ANALYSIS BY APPLICATION (USD MILLION)
2.1 DRIVER, RESTRAINT, CHALLENGE AND OPPORTUNITIES ANALYSIS
2.1.1 MARKET DRIVER ANALYSIS
2.1.2 MARKET RESTRAINT ANALYSIS
2.1.3 MARKET OPPORTUNITY
2.1.4 MARKET CHALLENGES
3.1 INDUSTRY TRENDS
3.1.1 SWOT ANALYSIS
3.1.2 PESTEL ANALYSIS
3.1.3 PORTER’S FIVE FORCES ANALYSIS
3.2 POTENTIAL MARKET AND GROWTH POTENTIAL ANALYSIS
4.1 COVID-19 ANALYSIS
5.1 GLOBAL MALIGNANT MESOTHELIOMA MARKET, SALES AREA, TYPE
5.2 MERGERS & ACQUISITIONS, PARTNERSHIPS, PRODUCT LAUNCH, AND COLLABORATION IN GLOBAL MALIGNANT MESOTHELIOMA MARKET
7.1 GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE AND SHARE (2018-2031) (USD MILLION)
8.1 GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
8.2 GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
9.1 GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
9.2 GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
10.1 GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE AND SHARE BY REGION (2018-2023) (USD MILLION)
10.2 GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE AND SHARE BY REGION (2024-2031) (USD MILLION)
11.1 NORTH AMERICA MALIGNANT MESOTHELIOMA MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
11.2 NORTH AMERICA MALIGNANT MESOTHELIOMA MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
11.3 NORTH AMERICA MALIGNANT MESOTHELIOMA MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
11.4 NORTH AMERICA MALIGNANT MESOTHELIOMA MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
11.5 NORTH AMERICA MALIGNANT MESOTHELIOMA MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
11.6 NORTH AMERICA MALIGNANT MESOTHELIOMA MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
12.1 EUROPE MALIGNANT MESOTHELIOMA MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
12.2 EUROPE MALIGNANT MESOTHELIOMA MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
12.3 EUROPE MALIGNANT MESOTHELIOMA MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
12.4 EUROPE MALIGNANT MESOTHELIOMA MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
12.5 EUROPE MALIGNANT MESOTHELIOMA MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
12.6 EUROPE MALIGNANT MESOTHELIOMA MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
13.1 ASIA PACIFIC MALIGNANT MESOTHELIOMA MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
13.2 ASIA PACIFIC MALIGNANT MESOTHELIOMA MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
13.3 ASIA PACIFIC MALIGNANT MESOTHELIOMA MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
13.4 ASIA PACIFIC MALIGNANT MESOTHELIOMA MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
13.5 ASIA PACIFIC MALIGNANT MESOTHELIOMA MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
13.6 ASIA PACIFIC MALIGNANT MESOTHELIOMA MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
14.1 LATIN AMERICA MALIGNANT MESOTHELIOMA MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)/p>
14.2 LATIN AMERICA MALIGNANT MESOTHELIOMA MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
14.3 LATIN AMERICA MALIGNANT MESOTHELIOMA MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
14.4 LATIN AMERICA MALIGNANT MESOTHELIOMA MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
14.5 LATIN AMERICA MALIGNANT MESOTHELIOMA MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
14.6 LATIN AMERICA MALIGNANT MESOTHELIOMA MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
15.1 MIDDLE EAST & AFRICA MALIGNANT MESOTHELIOMA MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
15.2 MIDDLE EAST & AFRICA MALIGNANT MESOTHELIOMA MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
15.3 MIDDLE EAST & AFRICA MALIGNANT MESOTHELIOMA MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
15.4 MIDDLE EAST & AFRICA MALIGNANT MESOTHELIOMA MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
15.5 MIDDLE EAST & AFRICA MALIGNANT MESOTHELIOMA MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
15.6 MIDDLE EAST & AFRICA MALIGNANT MESOTHELIOMA MARKET SIZE AND SHARE BY APPLICATION (2024-2031)< (USD MILLION)/p>
16.1 AstraZeneca Plc.
16.1.1 COMPANY DETAILS
16.1.2 FINANCIALS (USD MILLION)
16.1.3 PRODUCT SUMMARY
16.1.4 RECENT DEVELOPMENTS
16.2 Bristol-Myers Squibb Company
16.3 F. Hoffmann-La Roche Ltd.
16.4 Merck & Co., Inc.
16.5 Novartis AG
16.6 Pfizer Inc.
16.7 Sanofi
16.8 Eli Lilly and Company
16.9 Teva Pharmaceuticals
16.10 Boehringer Ingelheim GmbH
16.11 Mylan N.V.
16.12 Fresenius Kabi AG
16.13 Sun Pharmaceuticals Industries Ltd
16.14 Corden Pharma International GmbH
16.15 Concordia International Corp
16.16 Kyowa Hakko Kirin Co Ltd.
16.17 Polaris Pharmaceuticals, Inc.
16.18 MolMed SpA
16.19 Ono Pharmaceutical Co. Ltd
16.20 Nichi-Iko Pharmaceutical Co., Ltd
18.1 METHODOLOGY
18.2 RESEARCH DATA SOURCE
18.2.1 SECONDARY DATA
18.2.2 KEY DATA FROM SECONDARY
18.2.3 PRIMARY DATA
18.2.4 KEY DATA FROM PRIMARY
18.2.5 INDUSTRY INSIGHT FROM PROFESSIONAL LEADERS
18.2.6 MARKET ESTIMATION
18.2.7 MARKET ESTIMATION: TOP-DOWN AND BOTTOM-UP APPROACH
18.2.8 LEGAL DISCLAIMER
Market Segments
By Drug TypePemetrexed
Cisplatin
Carboplatin
Gemcitabine
Vinorelbine
Others
By Route of Administration
Oral
Parenteral
Companies
AstraZeneca Plc.
Bristol-Myers Squibb Company
F. Hoffmann-La Roche Ltd.
Merck & Co., Inc.
Novartis AG
Pfizer Inc.
Sanofi
Eli Lilly and Company
Teva Pharmaceuticals
Boehringer Ingelheim GmbH
Mylan N.V.
Fresenius Kabi AG
Sun Pharmaceuticals Industries Ltd
Corden Pharma International GmbH
Concordia International Corp
Kyowa Hakko Kirin Co Ltd.
Polaris Pharmaceuticals, Inc.
MolMed SpA
Ono Pharmaceutical Co. Ltd
Nichi-Iko Pharmaceutical Co., Ltd
BROWSE INDUSTRY
- PROACTIVE
- QUALITY & RELIABILITY
- GLOBAL OUTREACH
- COMPETITIVE PRICING
WHY CHOOSE US
We manage our resources 24/7 to identify issues and address them before they become problems.
We are committed to providing reliable and highly accurate data with an excellent quality control system.
6 Major regions and 40+ countries level analysis accomplished.
Our pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery.